Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52‐week open‐label study

Aims/Introduction Canagliflozin is a sodium–glucose cotransporter 2 inhibitor under development for the treatment of type 2 diabetes. Our aim was to examine its efficacy and safety as monotherapy or in combination with commonly used oral antihyperglycemic drugs in Japanese patients with type 2 diabe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of diabetes investigation 2015-03, Vol.6 (2), p.210-218
Hauptverfasser:	Inagaki, Nobuya, Kondo, Kazuoki, Yoshinari, Toru, Kuki, Hideki
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Canagliflozin Clinical medicine Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diet Dipeptidyl-peptidase IV Drug dosages FDA approval Hemoglobin Hypoglycemia Metabolism Peptidase R&D Research & development Sodium Sodium-glucose cotransporter Sodium–glucose cotransporter 2 inhibitor Studies Sulfonylurea Type 2 diabetes mellitus α-Glucosidase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!